Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: Effective asthma therapy in practice

Respiratory Medicine

Volumn 106, Issue SUPPL. 1, 2012, Pages

  Tamm, Michael ^a   Richards, David H ^b   Beghé, Bianca ^c   Fabbri, Leonardo ^c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Misbourne Solutions   (United Kingdom)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Airways; Bronchodilators; Combination therapy; Fluticasone propionate; Formoterol fumarate; Glucocorticosteroids; ICS LABA; Pharmacological profiles

Indexed keywords

BECLOMETASONE; BECLOMETASONE 17 MONOPROPIONATE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BECLOMETASONE PLUS FORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL FUMARATE; CICLESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; FORMOTEROL; FORMOTEROL FUMARATE PLUS MOMETASONE FUROATE; INDACATEROL; INDACATEROL PLUS MOMETASONE; ISOPRENALINE; MOMETASONE FUROATE; SALBUTAMOL; SALMETEROL; UNCLASSIFIED DRUG;

AIRWAY REMODELING; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL PRACTICE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INHIBITION; DRUG POTENTIATION; DRUG RECEPTOR BINDING; EUROPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MONOTHERAPY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; EVIDENCE-BASED MEDICINE; GLUCOCORTICOIDS; HUMANS; NEBULIZERS AND VAPORIZERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84871649139     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/S0954-6111(12)70005-7     Document Type: Article

References (100)

1. GINA Report, Global Strategy for Asthma Management and Prevention Available from: http://www.ginasthma.org/uploads/users/files/GINA-Report-2011. pdf y(accessed: 21 November 2011).
2. J Ankerst Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma J Asthma 42 2005 715 724
3. RA Pauwels, CG Lofdahl, DS Postma, AE Tattersfield, P O'Byrne, PJ Barnes et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group N Engl J Med 337 1997 1405 1411
4. A Woolcock, B Lundback, N Ringdal, LA Jacques Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids Am J Respir Crit Care Med 153 1996 1481 1488
5. AP Greening, PW Ind, M Northfield, G Shaw Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group Lancet 344 1994 219 224
6. EL Langmack, RJ Martin Heterogeneity of response to asthma controller therapy: clinical implications Curr Opin Pulm Med 16 2010 13 18
7. SC Lazarus, HA Boushey, JV Fahy, VM Chinchilli, RF Lemanske Jr, CA Sorkness et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial JAMA 285 2001 2583 2593
8. H Nelson, C Bonuccelli, F Radner, A Ottosson, KJ Carroll, TL Andersson et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials J Allergy Clin Immunol 125 2010 390 396 e8.
9. DB Price, D Hernandez, P Magyar, J Fiterman, KM Beeh, IG James et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma Thorax 58 2003 211 216
10. MJ Vaquerizo, P Casan, J Castillo, M Perpina, J Sanchis, V Sobradillo et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma Thorax 58 2003 204 210
11. D Price, SD Musgrave, L Shepstone, EV Hillyer, EJ Sims, RFT Gilbert et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy N Engl J Med 364 2011 1695 1707
12. SE Dahlén, B Dahlén, JM Drazen Asthma treatment guidelines meet the real world N Engl J Med 364 2011 1769 1770
13. HS Nelson, WW Busse, E Kerwin, N Church, A Emmett, K Rickard et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast J Allergy Clin Immunol 106 2000 1088 1095
14. JE Fish, E Israel, JJ Murray, A Emmett, R Boone, SW Yancey et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy Chest 120 2001 423 430
15. FM Ducharme, TJ Lasserson, CJ Cates Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma Cochrane Database Syst Rev 2006 CD003137
16. N Ringdal, A Eliraz, P Pruzinec, H-H Weber, PGH Mulder, M Akveld et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma Respir Med 97 2003 234 241
17. SP Peters, SJ Kunselman, N Icitovic, WC Moore, R Pascual, BT Ameredes et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma N Engl J Med 363 2010 1715 1726
18. HA Kerstjens, M Engel, R Dahl, P Paggiaro, E Beck, M Vandewalker et al. Tiotropium in asthma poorly controlled with standard combination therapy N Engl J Med 367 2012 1198 1207
19. Boehringer Ingelheim Pharmaceuticals I: SPIRIVA® Handi-Haler® (tiotropium bromide inhalation powder) 18 microgram Capsules for Respiratory Inhalation Available from: http://www.medicines.org.uk/emc/medicine/10039/spc (accessed: July2012).
20. G Huchon, H Magnussen, A Chuchalin, L Dymek, FB Gonod, J Bousquet Lung function and asthma control with beclomethasone and formoterol in a single inhaler Respir Med 103 2009 41 49
21. HS Nelson, KR Chapman, SD Pyke, M Johnson, JN Pritchard Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers J Allergy Clin Immunol 112 2003 29 36
22. C Marceau, C Lemière, D Berbiche, S Perreault, L Blais Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma J Allergy Clin Immunol 118 2006 574 581
23. KR Murphy, BG Bender Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence J Asthma Allergy 2 2009 63 72
24. SW Stoloff, DA Stempel, J Meyer, RH Stanford, JR Carranza Rosenzweig Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies J Allergy Clin Immunol 113 2004 245 251
25. DA Stempel, SW Stoloff, JR Carranza Rosenzweig, RH Stanford, KL Ryskina, AP Legorreta Adherence to asthma controller medication regimens Respir Med 99 2005 1263 1267
26. TJ Lasserson, CJ Cates, G Ferrara, L Casali Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children Cochrane Database Syst Rev 2010 CD004106
27. A Papi, P Paggiaro, G Nicolini, AM Vignola, LM Fabbri Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma Allergy 62 2007 1182 1188
28. A Papi, PL Paggiaro, G Nicolini, AM Vignola, LM Fabbri Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma Eur Respir J 29 2007 682 689
29. J Shepherd, G Rogers, R Anderson, C Main, J Thompson-Coon, D Hartwell et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over Health Technol Assess 12 2008 1 360 iii-iv
30. S Rohatagi, S Appajosyula, H Derendorf, S Szefler, R Nave, K Zech et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective J Clin Pharmacol 44 2004 37 47
31. JA van Noord, JJ Smeets, JA Raaijmakers, AM Bommer, FP Maesen Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action Eur Respir J 9 1996 1684 1688
32. M Palmqvist, G Persson, L Lazer, J Rosenborg, P Larsson, J Lotvall Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency Eur Respir J 10 1997 2484 2489
33. MA Giembycz, R Newton Beyond the dogma: novel beta2-adrenoceptor signalling in the airways Eur Respir J 27 2006 1286 1306
34. S Collins, MG Caron, RJ Lefkowitz Beta-adrenergic receptors in hamster smooth muscle cells are transcriptionally regulated by glucocorticoids J Biol Chem 263 1988 9067 9070
35. JC Mak, M Nishikawa, PJ Barnes Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung Am J Physiol 268 1995 L41 L46
36. IM Adcock, DA Stevens, PJ Barnes Interactions of glucocorticoids and beta 2-agonists Eur Respir J 9 1996 160 168
37. JN Baraniuk, M Ali, D Brody, J Maniscalco, E Gaumond, T Fitzgerald et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa Am J Respir Crit Care Med 155 1997 704 710
38. D Cheung, MC Timmers, AH Zwinderman, EH Bel, JH Dijkman, PJ Sterk Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyper-responsiveness in patients with mild asthma N Engl J Med 327 1992 1198 1203
39. JC Mak, M Nishikawa, H Shirasaki, K Miyayasu, PJ Barnes Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo J Clin Invest 96 1995 99 106
40. K Kalavantavanich, CM Schramm Dexamethasone potentiates high-affinity beta-agonist binding and g(s)alpha protein expression in airway smooth muscle Am J Physiol Lung Cell Mol Physiol 278 2000 L1101 L1106
41. G Horvath, ES Mendes, N Schmid, A Schmid, GE Conner, M Salathe et al. The effect of corticosteroids on the disposal of long-acting beta2-agonists by airway smooth muscle cells J Allergy Clin Immunol 120 2007 1103 1109
42. OS Usmani, K Ito, K Maneechotesuwan, M Ito, M Johnson, PJ Barnes et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy Am J Respir Crit Care Med 172 2005 704 712
43. M Roth, PR Johnson, JJ Rudiger, GG King, Q Ge, JK Burgess et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling Lancet 360 2002 1293 1299
44. M Kaur, JE Chivers, MA Giembycz, R Newton Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells Mol Pharmacol 73 2008 203 214
45. J Loven, N Svitacheva, A Jerre, A Miller-Larsson, SH Korn Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor Eur Respir J 30 2007 848 856
46. PJ Barnes Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids Eur Respir J 19 2002 182 191
47. A Sindi, DC Todd, P Nair Antiinflammatory effects of long-acting beta2-agonists in patients with asthma: a systematic review and metaanalysis Chest 136 2009 145 154
48. DS Postma, HA Kerstjens, NH ten Hacken Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol 378 2008 203 215
49. SS An, TR Bai, JH Bates, JL Black, RH Brown, V Brusasco et al. Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma Eur Respir J 29 2007 834 860
50. P Borger, N Miglino, M Baraket, JL Black, M Tamm, M Roth Impaired translation of CCAAT/enhancer binding protein alpha mRNA in bronchial smooth muscle cells of asthmatic patients J Allergy Clin Immunol 123 2009 45 63
51. M Roth, PR Johnson, P Borger, MP Bihl, JJ Rudiger, GG King et al. Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells N Engl J Med 351 2004 560 574
52. M Roth, J Zhong, P Borger, CT S'ng, M Tamm Formoterol reduces asthmatic airway smooth muscle cell proliferation through p27 (Kip) which is supported by steroids Eur Respir J 40 2012 abstract 4834.
53. M Roth, J Zhong, C S'ng, M Tamm Formoterol and fluticasone reduce the deposition of pro-inflammatory collagens Eur Respir J 40 2012 abstract 2182.
54. 2-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids Br J Pharmacol 153 2008 1090 1104
55. J Chakir, J Shannon, S Molet, M Fukakusa, J Elias, M Laviolette et al. Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression J Allergy Clin Immunol 111 2003 1293 1298
56. A Theophilus, A Moore, D Prime, S Rossomanno, B Whitcher, H Chrystyn Co-deposition of salmeterol and fluticasone propionate by a combination inhaler Int J Pharm 313 2006 14 22
57. PJ Barnes, IM Adcock, K Ito Histone acetylation and deacetylation: importance in inflammatory lung diseases Eur Respir J 25 2005 552 563
58. SP Umland, RP Schleimer, SL Johnston Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma Pulm Pharmacol Ther 15 2002 35 50
59. HW Kelly Comparison of inhaled corticosteroids: an update Ann Pharmacother 43 2009 519 527
60. H Derendorf, R Nave, A Drollmann, F Cerasoli, W Wurst Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma Eur Respir J 28 2006 1042 1050
61. H Derendorf Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide J Clin Pharmacol 47 2007 782 789
62. H Derendorf, PT Daley-Yates, LN Pierre, J Efthimiou Bioavailability and metabolism of mometasone furoate: pharmacology versus methodology J Clin Pharmacol 42 2002 383 387
63. M Hubner, G Hochhaus, H Derendorf Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids Immunol Allergy Clin North Am 25 2005 469 488
64. M Johnson Development of fluticasone propionate and comparison with other inhaled corticosteroids J Allergy Clin Immunol 101 1998 S434 S439
65. T Yzet, R Bouzerar, O Baledent, C Renard, DM Lumbala, E Nguyen-Khac et al. Dynamic measurements of total hepatic blood flow with Phase Contrast MRI Eur J Radiol 73 2010 119 124
66. GH Phillipps Structure-activity relationships of topically active steroids: the selection of fluticasone propionate Respir Med 84 Suppl A 1990 19 23
67. SereventAccuhaler. Summary of Product Characteristics Available from: http://www.medicines.org.uk/emc/medicine/91/SPC/Serevent+Accuhaler/ (accessed: 25 July 2012).
68. Oxis Turbohaler 6, inhalation powder. Summary of product charateristics Available from: http://www.medicines.org.uk/EMC/medicine/189/SPC/ Oxis%20Turbohaler%206,%20inhalation%20powder/ (accessed: 25 July 2012).
69. A Grove, LC McFarlane, BJ Lipworth Expression of the beta 2 adrenoceptor partial agonist/antagonist activity of salbutamol in states of low and high adrenergic tone Thorax 50 1995 134 138
70. Easyhaler Salbutamol 100mcg. Summary of product characteristics Available from: http://www.medicines.org.uk/emc/medicine/21084 (accessed: 25 July 2012).
71. M Palmqvist, T Ibsen, A Mellen, J Lotvall Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients Am J Respir Crit Care Med 160 1999 244 249
72. MJ Politiek, M Boorsma, R Aalbers Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction Eur Respir J 13 1999 988 992
73. JA van Noord, JJ Smeets, FP Maesen A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction Respir Med 92 1998 1348 1351
74. JR Beach, CL Bromly, AJ Avery, RW Reid, EH Walters, DJ Hendrick Speeds of action of single doses of formoterol and salbutamol compared with placebo in reversing methacholine-induced bronchoconstriction Pulm Pharmacol 9 1996 245 249
75. Foradil. Summary of product charateristics Available from: http://www.medicines.org.uk/EMC/medicine/1286/SPC/Foradil/ (accessed: 25 July 2012).
76. 2-adrenergic receptor function, response, and regulation J Allergy Clin Immunol 117 2006 18 24
77. RA Coleman, M Johnson, AT Nials, CJ Vardey Exosites: their current status, and their relevance to the duration of action of long-acting beta2-adrenoceptor agonists Trends Pharmacol Sci 17 1996 324 330
78. J Lotvall, J Ankerst Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients Respir Med 102 2008 449 456
79. 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients Respir Res 7 2006 110
80. M Masoli, M Williams, M Weatherall, R Beasley The 24 h duration of bronchodilator action of the budesonide/formoterol combination inhaler Respir Med 100 2006 20 25
81. M Cazzola, CP Page, L Calzetta, GM Matera Pharmacology and therapeutics of bronchodilators Pharmacol Rev 64 2012 450 504
82. M Cazzola, L Calzetta, MG Matera β(2)-adrenoceptor agonists: current and future direction Br J Pharmacol 163 2011 4 17
83. 2 adrenoceptor agonist, on small airways in human and rat precision-cut lung slices J Pharmacol Exp Ther 324 2008 270 275
84. D Lombardi, B Cuenoud, SD Krämer Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 38 2009 533 547
85. Onbrez Breezhaler 150 and 300 microgram inhalation powder, hard capsules. Summary of product characteristics Available from: http://www.medicines.org.uk/ EMC/medicine/23260/SPC/ Onbrez+Breezhaler+150+and+300+microgram+inhalation+powder, +hard+capsulesAUTHDATE (accessed: 25 July 2012).
86. C Frois, EQ Wu, S Ray, GL Colice Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol Clin Ther 31 2009 2779 2803
87. R Jaeschke, PM O'Byrne, F Mejza, P Nair, W Lesniak, J Brozek et al. The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis Am J Respir Crit Care Med 178 2008 1009 1016
88. S Dissanayake, B Grothe, K Kaiser Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma Respir Med 106 Suppl 1 2012 S20 S28
89. JN Pritchard The influence of lung deposition on clinical response J Aerosol Med 14 Suppl 1 2001 S19 S26
90. OS Usmani, MF Biddiscombe, JA Nightingale, SR Underwood, PJ Barnes Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols J Appl Physiol 95 2003 2106 2112
91. SP Newman, HK Chan In vitro/in vivo comparisons in pulmonary drug delivery J Aerosol Med Pulm Drug Deliv 21 2008 77 84
92. JP Mitchell, MW Nagel Particle size analysis of aerosols from medicinal inhalers KONA 22 2004 32 65
93. RJ Martin Therapeutic significance of distal airway inflammation in asthma J Allergy Clin Immunol 109 2002 S447 S460
94. PR Burgel, J de Blic, P Chanez, C Delacourt, P Devillier, A Didier et al. Update on the roles of distal airways in asthma Eur Respir Rev 18 2009 80 95
95. A Taylor, P Gustafsson Do all dry powder inhalers show the same pharmaceutical performance? Int J Clin Pract 59 2005 7 12
96. H Chrystyn, D Price Not all asthma inhalers are the same: factors to consider when prescribing an inhaler Prim Care Respir J 18 2009 243 249
97. H Chrystyn The Diskus(tm): a review of its position among dry powder inhaler devices Int J Clin Pract 61 2007 1022 1036
98. DA Lewis, D Ganderton, BJ Meakin, G Brambilla Modulite: a simple solution to a difficult problem Respiration 72 Suppl 1 2005 3 5
99. GL Colice Comparing inhaled corticosteroids Respir Care 45 2000 846 853
100. B Luijk, RD Kempsford, AM Wright, P Zanen, JW Lammers Duration of effect of single-dose inhaled fluticasone propionate on AMP-induced bronchoconstriction Eur Respir J 23 2004 559 564